For example, the poly-glycine-alanine aggregates cause a reduction in SV2 protein synaptic release leading to neuronal death that can be rescued by restoring SV2 levels, thus opening a possible early clinical ALS therapy (Jensen et al., 2020). The gene discussed is SV2A; the disease is amyotrophic lateral sclerosis.